Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

829 - Neoadjuvant radio-chemotherapy for esophageal cancer: a multicenter european study comparing PACLITAXEL/CARBOPLATIN , 5FU/CISPLATIN and FOLFOX.


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy;  Radiation Oncology

Tumour Site

Oesophageal Cancer


Pierre Allemann


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


P. Allemann1, S. Mantziari1, M. Winiker1, A.D. Wagner2, A. Digklia2, M. van Berge Henegouwen3, S.S. Gisbertz3, A. Slaman3, R. van Hillegersberg4, J.P. Ruurda4, H. Brenkman4, M. Nilsson5, K. Satoshi5, G. Piessen6, D. Collet7, C. Gronnier7, N. Carrere8, A. Marinho8, N. Demartines1, M. Schafer1

Author affiliations

  • 1 Visceral Surgery, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 2 Medical Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 3 Surgery, Academic Medical Center, Amsterdam/NL
  • 4 Surgery, University Medical Center Utrecht, Utrecht/NL
  • 5 Surgical Gastroenterology, Karolinska Institute, Huddinge/SE
  • 6 Chirurgie Digestive, C.H.U. Claude Huriez, 59037 - Lille/FR
  • 7 Digestive Surgery, University Hospital Bordeaux, Bordeaux/FR
  • 8 Oncological Surgery, CHU Toulouse, 31059 - Toulouse/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 829


Different regimens of neoadjuvant radio-chemotherapy are concurrently used prior to surgery for resectable, locally advanced esophageal cancer. Comparative data are scarce and to some extent conflicting, regarding toxicity and long-term outcomes when treating different subtypes. This study aimed to assess clinical tolerances and long-term survival of three commonly used combinations of neoadjuvant therapies.


Patients operated from January 2004 to December 2014 who underwent neoadjuvant radio-chemotherapy with Paclitaxel/Carboplatin, or 5FU/Cisplatin, or FOLFOX for adenocarcinoma or squamous cell carcinoma were included. Seven European centers colligated data of 1188 patients. Cases with missing data (n = 147) or death <30 days postoperative (n = 51) were excluded. The primary outcome was the overall survival; secondary outcomes were the completeness and toxicity of neoadjuvant treatment, the disease free survival and the recurrence timing and pattern.


Of the 990 eligible patients, Paclitaxel/Carboplatin was used in 598 patients (60%), 5FU/Cisplatin in 331 (33%) and Folfox in 61 (7%). The groups received a median radiation dose of 41.4 Gy, 45 Gy and 45 Gy (p = 0.65). Adenocarcinoma was the most frequent subtype (69%). No differences were detected in median overall survival (41 months, 34 months and 46 months, p = 0.251). Comparing the overall survival of the three regimens for adenocarcinoma vs squamous cell carcinoma, no difference was observed as well. There were no differences in chemotherapy-related morbidity (13%, 11% and 9%, p = 0.57), chemotherapy completeness (85%, 88% and 90%, p = 0.542) and radiotherapy completeness (98%, 99% and 96%, p = 0.9) between the three groups. Recurrence rates were similar (42%, 46% and 34%, p = 0.169), but median disease-free survival was improved in the 5FU/Cisplatin group (10 months, 18 months and 13 months, p < 0.001).


The overall survival did not differ between different neoadjuvant treatments. Moreover, no advantage of one regimen for specific cancer subtypes was observed. At most, a modest clinical advantage of 5-FU/Cisplatin was observed for disease-free survival.

Clinical trial identification

Research Registry number: 2157.

Legal entity responsible for the study

NeoTEC study group, Lausanne University Hospital, Lausanne, Switzerland.


Has not received any funding.

Editorial Acknowledgement


A.D. Wagner: Research funding: Roche; Consultant or advisory: Lilly, Celgene, Merck, Bristol-Myers Squibb, Pfizer, Servier Shire. M. van Berge Henegouwen: Medtronic, Olympus research grant (other studies). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.